American Journal of Hematology最新文献

{"title":"Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","authors":"Arnon Nagler,&nbsp;Maud Ngoya,&nbsp;Jacques-Emmanuel Galimard,&nbsp;Myriam Labopin,&nbsp;Igor Wolfgang Blau,&nbsp;Nicolaus Kröger,&nbsp;Tobias Gedde-Dahl,&nbsp;Thomas Schroeder,&nbsp;David Burns,&nbsp;Urpu Salmenniemi,&nbsp;Alessandro Rambaldi,&nbsp;Goda Choi,&nbsp;Régis Peffault de Latour,&nbsp;Jan Vydra,&nbsp;Henrik Sengeloev,&nbsp;Matthias Eder,&nbsp;Stephan Mielke,&nbsp;Edouard Forcade,&nbsp;Alexander Kulagin,&nbsp;Fabio Ciceri,&nbsp;Mohamad Mohty","doi":"10.1002/ajh.27383","DOIUrl":"10.1002/ajh.27383","url":null,"abstract":"<p>We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy, and 6342 without (No PTCy). The patients in the PTCy group were younger, 52.7 versus 56.6 years (<i>p</i> &lt; .001). There were more 9/10 donors in the PTCy group, 33.8% versus 16.4% (<i>p</i> &lt; .001), and more received myeloablative conditioning, 61.7% versus 50.2% (<i>p</i> &lt; .001). In the No PTCy group, 87.7% of patients received in vivo T-cell depletion. Neutrophil and platelet engraftment were lower in the PTCy versus No PTCy group, 93.8% and 80.9% versus 97.6% and 92.6% (<i>p</i> &lt; .001). RI was not significantly different in the PTCy versus the No PTCy group, hazard ratio (HR) of 1.11 (95% confidence interval [CI] 0.9–1.37) (<i>p</i> = .31). Acute GVHD grades II–IV and III–IV, were significantly lower in the PTCy versus the No PTCy group, HR of 0.74 (95% CI 0.59–0.92, <i>p</i> = .007) and HR = 0.56 (95% CI 0.38–0.83, <i>p</i> = .004), as were total and extensive chronic GVHD, HRs of 0.5 (95% CI 0.41–0.62, <i>p</i> &lt; .001) and HR = 0.31 (95% CI 0.22–0.42, <i>p</i> &lt; .001). Non-relapse mortality (NRM) was significantly lower with PTCy versus the No PTCy group, HR of 0.67 (95% CI 0.5–0.91, <i>p</i> = .007). GVHD-free, relapse-free survival (GRFS) was higher in the PTCy versus the No PTCy group, HR of 0.69 (95% CI 0.59–0.81, <i>p</i> = .001). Leukemia-free survival (LFS) and overall survival (OS) did not differ between the groups. In summary, we observed comparable RI, OS, and LFS, significantly lower incidences of GVHD and NRM, and significantly higher GRFS in AML patients undergoing unrelated donor-hematopoietic stem cell transplantation with PTCy versus No PTCy GVHD prophylaxis.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival”","authors":"","doi":"10.1002/ajh.27405","DOIUrl":"10.1002/ajh.27405","url":null,"abstract":"<p>Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. <i>Am J Hematol</i>. 2023;98(3):413–420. doi: 10.1002/ajh.26806.</p><p>In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21).</p><p>We apologize for this error.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27405","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients”","authors":"","doi":"10.1002/ajh.27401","DOIUrl":"10.1002/ajh.27401","url":null,"abstract":"<p>Mellors PW, Kourelis T, Go RS, et al. Characteristics and risk factors for thrombosis in POEMS syndrome: a retrospective evaluation of 230 patients. <i>Am J Hematol</i>. 2022;97(2):209-215.</p><p>In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21).</p><p>We apologize for this error.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27401","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia","authors":"Paola Guglielmelli,&nbsp;Barbara Mora,&nbsp;Francesca Gesullo,&nbsp;Francesco Mannelli,&nbsp;Giuseppe Gaetano Loscocco,&nbsp;Leonardo Signori,&nbsp;Chiara Pessina,&nbsp;Ilaria Colugnat,&nbsp;Raffaela Aquila,&nbsp;Manjola Balliu,&nbsp;Chiara Maccari,&nbsp;Simone Romagnoli,&nbsp;Chiara Paoli,&nbsp;Elena Nacca,&nbsp;Lorenzo Fagiolo,&nbsp;Margherita Maffioli,&nbsp;Tiziano Barbui,&nbsp;Francesco Passamonti,&nbsp;Alessandro M. Vannucchi","doi":"10.1002/ajh.27400","DOIUrl":"10.1002/ajh.27400","url":null,"abstract":"<p>The variant allele frequency (VAF) of driver mutations (<i>JAK2, CALR</i>) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains debated. We prospectively measured changes in <i>JAK2</i> and <i>CALR</i> VAF in 77 patients with polycythemia vera and essential thrombocythemia, treated with ruxolitinib for a median of 8 years, and assessed correlation with complete clinical and hematological response (CCHR) and outcomes. At last observation time, <i>JAK2</i> VAF reduced overall from a median of 68% (range, 20%–99%) to 3.5% (0%–98%). A profound and durable MR (DMR; defined as a VAF stably ≤2%), including complete MR in 8%, was achieved in 20% of the patients, a partial MR (PMR; VAF reduction &gt;50% of the baseline level) in 25%, and 56% had no molecular response (NMR). A CCHR was reached by 69% overall, independently of any degree of MR achieved; conversely, a DMR correlated with longer duration of CCHR and, most importantly, with reduced rate of progression to myelofibrosis and with longer myelofibrosis-free, event-free and progression-free survival. Achievement of PMR also had some favorable impact on outcomes, compared to NMR. A baseline <i>JAK2</i> VAF &lt;50%, and a VAF reduction of ≥35% after 2 years of treatment, predicted for the achievement of DMR and reduced progression to myelofibrosis. Overall, these findings support the clinical value of achieving profound, durable MR and its consideration as surrogate endpoint in future clinical trials.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting anemia in myeloid neoplasms","authors":"Naseema Gangat,&nbsp;Ayalew Tefferi","doi":"10.1002/ajh.27408","DOIUrl":"10.1002/ajh.27408","url":null,"abstract":"<p>Anemia-directed therapeutic approaches targeting the TGF-β-SMAD and HIF-PH pathways.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27408","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study","authors":"Aung M. Tun,&nbsp;Romil D. Patel,&nbsp;Frederique St-Pierre,&nbsp;Evguenia Ouchveridze,&nbsp;Alex Niu,&nbsp;Thorunn Thordardottir,&nbsp;Jennifer Obasi,&nbsp;Allison Rosenthal,&nbsp;Priyanka A. Pophali,&nbsp;Timothy S. Fenske,&nbsp;Reem Karmali,&nbsp;Sairah Ahmed,&nbsp;Patrick B. Johnston","doi":"10.1002/ajh.27381","DOIUrl":"10.1002/ajh.27381","url":null,"abstract":"<p>Chimeric antigen receptor T-cell (CAR-T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B-cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR-T therapy in older patients with RR LBCL in the real-world setting. Patients aged ≥65 years with RR LBCL, treated with anti-CD19 CAR-T therapy at 7 US institutions were included in this multicenter, retrospective, observational study. In total, 226 patients were included. Median age at infusion was 71 years (range 65–89). Best objective and complete response rates were 86% and 62%, respectively. Median follow-up after infusion was 18.3 months. The median progression-free survival (PFS) was 6.9 months, with 6- and 12-month PFS estimates of 54% and 44%, respectively. The nonrelapse mortality (NRM) rate was 10.9% at day 180, primarily due to infections, and not impacted by the age groups. Grade ≥3 cytokine release syndrome and neurotoxicity occurred in 7% and 26%, respectively. In univariate analysis, no significant difference in PFS was seen regardless of the age groups or CAR-T type, whereas ECOG PS ≥2, elevated LDH, bulky disease, advanced stage, extranodal involvement, the need for bridging therapy, and prior bendamustine exposure were associated with shorter PFS. These findings support the use of CAR-T in older patients, including those aged ≥80 years. The age at CAR-T therapy did not influence safety, survival, and NRM outcomes. Older patients should not be excluded from receiving CAR-T therapy solely based on their chronological age.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)”","authors":"","doi":"10.1002/ajh.27406","DOIUrl":"10.1002/ajh.27406","url":null,"abstract":"<p>Visram A, Hayman SR, Dispenzieri A, et al. Am J Hematol. 2023;98(8):1277-1285. doi: 10.1002/ajh.26990.</p><p>In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21).</p><p>We apologize for this error.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27406","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141246236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL","authors":"Karin Bauer,&nbsp;Alexander Hauswirth,&nbsp;Karoline V. Gleixner,&nbsp;Georg Greiner,&nbsp;Johannes Thaler,&nbsp;Peter Bettelheim,&nbsp;Yüksel Filik,&nbsp;Elisabeth Koller,&nbsp;Gregor Hoermann,&nbsp;Philipp B. Staber,&nbsp;Wolfgang R. Sperr,&nbsp;Felix Keil,&nbsp;Peter Valent","doi":"10.1002/ajh.27385","DOIUrl":"10.1002/ajh.27385","url":null,"abstract":"<p>Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life-threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti-leukemic efficacies of the small-molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient-derived AML and ALL cells, including CD34⁺/CD38⁻ and CD34⁺/CD38⁺ leukemic stem and progenitor cells, independent of the type (variant) of leukemia or molecular driver expressed in leukemic cells. Moreover, we found that dBET6 overcomes osteoblast-induced drug resistance in AML and ALL cells, regardless of the type of leukemia or the drug applied. Most promising cooperative or even synergistic drug combination effects were seen with dBET6 and the <i>FLT3</i> ITD blocker gilteritinib in <i>FLT3</i> ITD-mutated AML cells, and with dBET6 and the multi-kinase blocker ponatinib in <i>BCR::ABL1</i>+ ALL cells. Finally, all BRD4-targeting drugs suppressed interferon-gamma- and tumor necrosis factor-alpha-induced expression of the resistance-related checkpoint antigen PD-L1 in AML and ALL cells, including LSC. In all assays examined, the BRD4 degrader dBET6 was a superior anti-leukemic drug compared with dBET1 and JQ1. Together, BRD4 degraders may provide enhanced inhibition of multiple mechanisms of therapy resistance in AML and ALL.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27385","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasmablastic lymphoma in the pleural cavity","authors":"Aditi Manjeri,&nbsp;Shir Ying Lee,&nbsp;Siok-Bian Ng,&nbsp;Chun-Tsu Lee","doi":"10.1002/ajh.27387","DOIUrl":"10.1002/ajh.27387","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study","authors":"Lauren Véronèse,&nbsp;Hedi Bensaber,&nbsp;Louis-Thomas Dannus,&nbsp;Gaetan Giannone,&nbsp;Christopher Choiset,&nbsp;Corentin Grimpret,&nbsp;Nassera Abermil,&nbsp;Estelle Balducci,&nbsp;Audrey Bidet,&nbsp;Elise Chapiro,&nbsp;Lucile Couronné,&nbsp;Agnès Daudignon,&nbsp;Nathalie Douet-Gilbert,&nbsp;Virginie Eclache,&nbsp;Baptiste Gaillard,&nbsp;Jean-Baptiste Gaillard,&nbsp;Faten Hsoumi,&nbsp;Christine Lefebvre,&nbsp;Nathalie Nadal,&nbsp;Marie-Joelle Mozziconacci,&nbsp;Dominique Penther,&nbsp;Bénédicte Ribourtout,&nbsp;Steven Richebourg,&nbsp;Lauren Rigollet,&nbsp;Christine Terre,&nbsp;Gwendoline Soler,&nbsp;Olivier Tournilhac,&nbsp;Romain Guièze,&nbsp;Florence Nguyen-Khac,&nbsp;Andrei Tchirkov","doi":"10.1002/ajh.27384","DOIUrl":"10.1002/ajh.27384","url":null,"abstract":"<p>The classical (14;19)(q32;q13)/IGH::<i>BCL3</i> or variant translocations, leading to the constitutive activation of BCL3 protein, are rare recurrent chromosomal abnormalities observed in mature B-cell lymphoproliferative disorders, mainly chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).<span>¹</span> <i>BCL3</i>-CLL presents with specific features, such as atypical morphology of lymphocytes, trisomy 12 (+12), complex karyotype (CK), unmutated immunoglobulin heavy chain genes (UM-IGHV), or stereotypic subset. <i>BCL3</i>-MZL presentation is also atypical and shares features with CLL such as CD5 expression (CD5+), leukemic burden, and +12. The molecular landscape of <i>BCL3</i>-translocation malignancies remains unexplored. Using a targeted next-generation sequencing (NGS), we analyzed here the mutational spectrum of <i>BCL3</i> disorders in the largest retrospective cohort documented so far.</p><p>A total of 114 patients were included in our study (Supplemental Table S1). The clinical presentations form a continuous spectrum from CLL (<i>n</i> = 73) and MZL (<i>n</i> = 37) to de novo diffuse large B-cell lymphoma (DLBCL) consisting of transformed MZL (<i>n</i> = 2) and Richter transformation (<i>n</i> = 1). One patient had primary B-cell mediastinal lymphoma. Importantly, atypical CLLs, with a modified Matutes score of 3, and CD5+ MZLs, all of them with leukemic phase, represented the core of the cohort (<i>n</i> = 58). UM-IGHV is the rule, with a biased use of the stereotyped IGHV4-39 rearrangement belonging to subset #8 among the CLLs subgroup. Patients tend to be younger than reported in the literature.<span>^{2, 3}</span> Median overall survival (OS), calculated from the time of diagnosis (160 months) or karyotype analysis (79 months), was longer than in previous reports,<span>^{1, 4}</span> which may be related to the overall improvement in therapeutic strategies. Median OS was similar for both CLL and MZL patients (78 vs. 85 months, <i>p</i> = NS).</p><p><i>BCL3</i>-translocations encountered 112 classical and six variant translocations (Supplemental Figure S1 and Table S2). Based on the recommendations of the International System for Human Cytogenomic Nomenclature, the <i>BCL3</i>-translocation was considered the primary clonal event (i.e., present in the stemline karyotype) in 85% of cases, frequently associated with additional aberrations (91.2%), mainly +12 (66.6%) and CK (44.7%). The most common recurrent abnormalities of CLL (i.e., del(13q)) and MZL (del(7q)) are remarkably rare. Overall, we confirmed many previous observations from smaller series.<span>^{1, 4}</span></p><p>NGS analysis (<i>n</i> = 95) demonstrated mutations in a single gene (26.3% of patients), two genes (39%), and three or four genes (16.8%). We observed 182 variants in 78 (82.1%) patients (Figure 1A, Supplemental Table S3), with a prevalence of <i>NOTCH1</i> (41%), followed by <i>BRAF</i> (26.3%), <i>TP53</i","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":null,"pages":null},"PeriodicalIF":10.1,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.27384","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}